Physician profile
Michael Gus Comas
NPI 1912904657
$318.99
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.10 · 2020: $11.02 · 2021: $281 · 2022: $16.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.74 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.83 | 2019-2021 | |
| Novo Nordisk INC | $15.60 | 2021 | |
| Sanofi Pasteur INC. | $13.94 | 2021 | |
| Esperion Therapeutics, INC. | $13.62 | 2021 | |
| Lilly USA, LLC | $13.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Comas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.